We treated 93 children with nephropathic cystinosis with oral cysteamine (mean dose, 51.3 mg per kilogram of body weight per day) for up to 73 months. This agent is known to be effective in depleting cells of cystine. In our study, the mean cystine depletion from leukocytes was 82 percent. A historical control group of 55 children received either ascorbic acid (27 children) or placebo (28). At age six, 2 of 17 controls had a serum creatinine level less than 1.0 mg per deciliter, as compared with 17 of 27 patients treated with cysteamine for at least one year (odds ratio, 12.8; 95 percent confidence interval, 2.1 to 33.9). At the end of the study, creatinine clearance was higher in the cysteamine group than in the control group (38.5 vs. 29.7 ml per minute per 1.73 m2; 95 percent confidence limits on the difference, 1.8 and 15.8), even though the cysteamine group was on average 1.4 years older than the control group. Cysteamine also improved growth; those in the cysteamine group between two and three years of age grew at 93 percent of the normal velocity, as compared with 54 percent in the control group. Fourteen percent of the patients could not tolerate the taste and smell of cysteamine. Concurrent controls treated in a blinded fashion with a placebo were not included in this study. With this limitation in mind, we conclude that oral cysteamine, by depleting cells of cystine, helps maintain renal glomerular function, improves growth, and constitutes the current treatment of choice for nephropathic cystinosis.
This article has been cited by other articles:
Taranta, A., Petrini, S., Palma, A., Mannucci, L., Wilmer, M. J., De Luca, V., Diomedi-Camassei, F., Corallini, S., Bellomo, F., van den Heuvel, L. P., Levtchenko, E. N., Emma, F.
(2008). Identification and subcellular localization of a new cystinosin isoform. Am. J. Physiol. Renal Physiol.
294: F1101-F1108
[Abstract][Full Text]
Gahl, W. A., Balog, J. Z., Kleta, R.
(2007). Nephropathic Cystinosis in Adults: Natural History and Effects of Oral Cysteamine Therapy. ANN INTERN MED
147: 242-250
[Abstract][Full Text]
Ueda, M., O'Brien, K., Rosing, D. R., Ling, A., Kleta, R., McAreavey, D., Bernardini, I., Gahl, W. A.
(2006). Coronary Artery and Other Vascular Calcifications in Patients with Cystinosis after Kidney Transplantation. CJASN
1: 555-562
[Abstract][Full Text]
Meikle, P. J., Ranieri, E., Simonsen, H., Rozaklis, T., Ramsay, S. L., Whitfield, P. D., Fuller, M., Christensen, E., Skovby, F., Hopwood, J. J.
(2004). Newborn Screening for Lysosomal Storage Disorders: Clinical Evaluation of a Two-Tier Strategy. Pediatrics
114: 909-916
[Abstract][Full Text]
Tsilou, E T, Thompson, D, Lindblad, A S, Reed, G F, Rubin, B, Gahl, W, Thoene, J, Del Monte, M, Schneider, J A, Granet, D B, Kaiser-Kupfer, M I
(2003). A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis. Br. J. Ophthalmol.
87: 28-31
[Abstract][Full Text]
Cherqui, S., Sevin, C., Hamard, G., Kalatzis, V., Sich, M., Pequignot, M. O., Gogat, K., Abitbol, M., Broyer, M., Gubler, M.-C., Antignac, C.
(2002). Intralysosomal Cystine Accumulation in Mice Lacking Cystinosin, the Protein Defective in Cystinosis. Mol. Cell. Biol.
22: 7622-7632
[Abstract][Full Text]
Geelen, J. M., Monnens, L. A. H., Levtchenko, E. N.
(2002). Follow-up and treatment of adults with cystinosis in the Netherlands. Nephrol Dial Transplant
17: 1766-1770
[Abstract][Full Text]
Kleta, R., Gahl, W. A.
(2002). Cystinosis: Antibodies and Healthy Bodies. J. Am. Soc. Nephrol.
13: 2189-2191
[Full Text]
Gahl, W. A., Thoene, J. G., Schneider, J. A.
(2002). Cystinosis. NEJM
347: 111-121
[Full Text]
Anikster, Y., Lacbawan, F., Brantly, M., Gochuico, B. L., Avila, N. A., Travis, W., Gahl, W. A.
(2001). Pulmonary Dysfunction in Adults With Nephropathic Cystinosis. Chest
119: 394-401
[Abstract][Full Text]
Chang, M. H.Y., Bindloss, C. A., Grabowski, G. A., Qi, X., Winchester, B., Hopwood, J. J., Meikle, P. J.
(2000). Saposins A, B, C, and D in Plasma of Patients with Lysosomal Storage Disorders. Clin. Chem.
46: 167-174
[Abstract][Full Text]
Meikle, P. J., Brooks, D. A., Ravenscroft, E. M., Yan, M., Williams, R. E., Jaunzems, A. E., Chataway, T. K., Karageorgos, L. E., Davey, R. C., Boulter, C. D., Carlsson, S. R., Hopwood, J. J.
(1997). Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker. Clin. Chem.
43: 1325-1335
[Abstract][Full Text]
Soohoo, N., Schneider, J. A., Kaplan, R. M.
(1997). A Cost-Effectiveness Analysis of the Orphan Drug Cysteamine in the Treatment of Infantile Cystinosis. Med Decis Making
17: 193-198
[Abstract]
Pisoni, R. L., Park, G. Y., Velilla, V. Q., Thoene, J. G.
(1995). Detection and Characterization of a Transport System Mediating Cysteamine Entry into Human Fibroblast Lysosomes. J. Biol. Chem.
270: 1179-1184
[Abstract][Full Text]
Markello, T. C., Bernardini, I. M., Gahl, W. A.
(1993). Improved Renal Function in Children with Cystinosis Treated with Cysteamine. NEJM
328: 1157-1162
[Abstract][Full Text]
Previous
